Evaluation of portal vein invasion of distal cholangiocarcinoma as borderline resectability

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 4, 2015, Pages 294-300

  Miura, Fumihiko ^a   Sano, Keiji ^a   Amano, Hodaka ^a   Toyota, Naoyuki ^a   Wada, Keita ^a   Yoshida, Masahiro ^b   Hayano, Koichi ^c   Matsubara, Hisahiro ^c   Takada, Tadahiro ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Borderline respectability; Distal cholangiocarcinoma; Portal vein invasion; Prognostic factor

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PANCREATICODUODENECTOMY; PORTAL VEIN; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR INVASION; UNIVARIATE ANALYSIS; VERY ELDERLY; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; CLINICAL TRIAL; EPIDEMIOLOGY; INTRAHEPATIC BILE DUCT; JAPAN; KAPLAN MEIER METHOD; LIVER RESECTION; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; TRENDS;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HEPATECTOMY; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM INVASIVENESS; PANCREATICODUODENECTOMY; PORTAL VEIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84925857585     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.198     Document Type: Article

References (40)

1. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224: 463-473; discussion 73-5.
2. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008; 206: 833-846; discussion 46-8.
3. Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013; 20: 590-600.
4. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010; 103: 469-474.
5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362: 1273-1281.
6. Ebata T, Nagino M, Nishio H, Igami T, Yokoyama Y, Nimura Y,. Pancreatic and duodenal invasion in distal bile duct cancer: paradox in the tumor classification of the American Joint Committee on Cancer. World J Surg. 2007; 31: 2008-2015.
7. Kurosaki I, Hatakeyama K, Minagawa M, Sato D,. Portal vein resection in surgery for cancer of biliary tract and pancreas: special reference to the relationship between the surgical outcome and site of primary tumor. J Gastrointest Surg. 2008; 12: 907-918.
8. Bahra M, Jacob D, Langrehr JM, Neumann UP, Neuhaus P,. Carcinoma of the distal and middle bile duct: surgical results, prognostic factors, and long-term follow-up. J Hepatobiliary Pancreat Surg. 2008; 15: 501-507.
9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A,. Distal bile duct. In: American Cancer Society, editor. AJCC cancer staging manual, 7th edn. New York: Springer-Verlag; 2010. p. 227-233.
10. Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008; 15: 41-54.
11. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13: 1035-1046.
12. Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kobayashi T, et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci. 2011; 18: 567-574.
13. Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas. 2009; 38: 282-288.
14. Motoi F, Unno M, Takahashi H, Okada T, Wada K, Sho M, et al. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2014; 21: 148-158.
15. Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012; 203: 132-139.
16. Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park do H, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012; 152: 851-862.
17. Miyazaki M, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery. 2007; 141: 581-588.
18. Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010; 252: 115-123.
19. de Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer. 2012; 118: 4737-4747.
20. Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schlieker W, et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol. 2012; 19: 1602-1608.
21. Tashiro S, Uchino R, Hiraoka T, Tsuji T, Kawamoto S, Saitoh N, et al. Surgical indication and significance of portal vein resection in biliary and pancreatic cancer. Surgery. 1991; 109: 481-487.
22. Bachellier P, Nakano H, Oussoultzoglou PD, Weber JC, Boudjema K, Wolf PD, et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg. 2001; 182: 120-129.
23. Todoroki T, Kawamoto T, Koike N, Fukao K, Shoda J, Takahashi H,. Treatment strategy for patients with middle and lower third bile duct cancer. Br J Surg. 2001; 88: 364-370.
24. Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S,. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg. 2002; 137: 69-73.
25. Choi SB, Park SW, Kim KS, Choi JS, Lee WJ,. The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection. J Surg Oncol. 2009; 99: 335-342.
26. Nomura T, Tsuchiya Y, Nashimoto A, Yabusaki H, Takii Y, Nakagawa S, et al. Prognostic factors for radical resection of middle and distal bile duct cancer. Hepatogastroenterology. 2009; 56: 294-298.
27. Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 1999; 229: 613-622; discussion 22-4.
28. Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, et al. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas. 2002; 25: 366-372.
29. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg. 1996; 223: 154-162.
30. Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Tajima H, Miwa K,. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg. 1999; 229: 76-83.
31. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Sueda T,. Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J Surg. 2007; 31: 337-342; discussion 43-4.
32. Qiao QL, Zhang TP, Guo JC, Zhan HX, Zhao JX, Liu YC, et al. Prognostic factors after pancreatoduodenectomy for distal bile duct cancer. Am Surg. 2011; 77: 1445-1448.
33. Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M,. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann Surg Oncol. 2007; 14: 1212-1219.
34. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; 245: 755-762.
35. Shimizu Y, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M,. The morbidity, mortality, and prognostic factors for ampullary carcinoma and distal cholangiocarcinoma. Hepatogastroenterology. 2008; 55: 699-703.
36. Kawai M, Tani M, Kobayashi Y, Tsuji T, Tabuse K, Horiuchi T, et al. The ratio between metastatic and examined lymph nodes is an independent prognostic factor for patients with resectable middle and distal bile duct carcinoma. Am J Surg. 2010; 199: 447-452.
37. Hong SM, Pawlik TM, Cho H, Aggarwal B, Goggins M, Hruban RH, et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery. 2009; 146: 250-257.
38. Park SW, Park YS, Chung JB, Kang JK, Kim KS, Choi JS, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology. 2004; 51: 1612-1618.
39. Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005; 137: 396-402.
40. Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013; 20: 318-324.